Analysts Set vTv Therapeutics Inc. (NASDAQ:VTVT) Target Price at $56.67

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $56.6667.

VTVT has been the subject of a number of recent analyst reports. Zacks Research lowered vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research report on Monday, May 18th. Rodman & Renshaw assumed coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price for the company. Wall Street Zen raised shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, BTIG Research lifted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th.

vTv Therapeutics Price Performance

NASDAQ:VTVT opened at $30.73 on Friday. The firm has a 50-day moving average of $33.79 and a two-hundred day moving average of $35.17. The stock has a market cap of $121.08 million, a P/E ratio of -33.04 and a beta of 0.25. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, beating the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. As a group, equities analysts expect that vTv Therapeutics will post -2.19 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics in the 4th quarter valued at about $731,000. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics during the fourth quarter worth about $221,000. Finally, Geode Capital Management LLC grew its stake in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. 17.51% of the stock is owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.